Zeitpunkt: 23.04.21 15:47
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Spam
Link: Nutzungsbedingungen
|
Zahlen für Q1/21
Surface Oncology continues to project that current cash, cash equivalents and an anticipated near-term milestone from GSK are sufficient to fund the Company through 2023.
investors.surfaceoncology.com/...ial-results-and-corporate-11
Zahlen für Q2/21
Surface Oncology continues to project that current cash, cash equivalents and an anticipated near-term milestone from GSK are sufficient to fund the Company through 2023.
- Investigational New Drug (IND) filing for GSK4381562 formerly, SRF813, targeting the PVRIG checkpoint and partnered with GlaxoSmithKline, anticipated in 2H 2021
- Data update from Phase 1 study of SRF617 anticipated in late 2021
investors.surfaceoncology.com/...ial-results-and-corporate-12
Zahlen für Q3/21
-Data update for SRF617 anticipated at the European Society for Medical Oncology Immuno-Oncology Congress taking place December 8-11, 2021
investors.surfaceoncology.com/...ial-results-and-corporate-13
Zahlen für Q4/21
- Company continues to guide to cash runway through 2023
investors.surfaceoncology.com/...ial-results-and-corporate-14
SURF bekommt 30 Mio. $ Meilensteinzahlung von GSK
investors.surfaceoncology.com/...lion-milestone-first-patient
Zahlen für Q1/22
- Cash runway extended into 2024
- $21 million raised in the quarter through ATM facility
investors.surfaceoncology.com/...ial-results-and-corporate-15
Zahlen für Q2/22
investors.surfaceoncology.com/...nancial-results-and-business
SRF617 wird auf Eis gelegt
endpts.com/...ech-halts-cd39-work-on-one-of-its-crown-jewels/
www.fiercebiotech.com/biotech/...rce-drops-antitumor-antibody
Zahlen für Q3/22
investors.surfaceoncology.com/node/9076/html
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
54 | SURF 4,94$ (-33%) | Vassago | Balu4u | 03.08.23 12:19 |